The Zepbound Dosage Chart: From Starting Dose to Units on a Vial

By the Affordable GLP-1 Providers desk · label and trial figures human-verified before launch per our editorial policy · not medical advice

Zepbound now ships two ways — auto-injector pens and single-dose vials — and the vial route dragged syringe units into a conversation that used to be one click. Here is the chart, the vial reality, and a hard line about the math we refuse to do.

The ladder is the tirzepatide ladder

Zepbound titrates exactly as Mounjaro does: 2.5 mg weekly ×4 weeks, then 5 mg, then optional +2.5 mg steps at ≥4-week intervals to a 15 mg maximum, with 5/10/15 mg as maintenance doses. Its distinct indications — chronic weight management, and obstructive sleep apnea in obesity — change who it’s for, not how it climbs.

Pens versus single-dose vials

The auto-injector pen is fixed-dose: press, done, no units involved. The single-dose vials (sold through Lilly’s direct self-pay channel at the lower price points) contain one dose drawn with the supplied syringe following the Instructions for Use — the entire labeled vial is the dose. "Units on a vial" in the brand context means following that IFU, not performing conversions.

The math we will not print

For compounded tirzepatide, concentration varies by pharmacy — 10 mg/mL here, 17 mg/mL there — and the FDA has documented dosing errors from patients converting milligrams to syringe units themselves. So this page draws the line explicitly: no conversion tables, no unit calculators, ever. The only valid instructions are printed on your pharmacy’s label, and the only valid explainer is that pharmacy’s or your prescriber’s.

Cost across the rungs

Because Lilly’s direct vial pricing differs by dose while most compounded programs price flat or by ladder, this chart doubles as a budgeting document. The honest comparison is brand-direct at your maintenance dose versus a program’s all-in price at that same dose — the savings tool runs both, against the price people actually pay rather than the list nobody does.

Missed doses and the sleep-apnea indication

Missed-dose handling follows the tirzepatide rule (take within roughly 4 days, else skip — verify your label’s wording). For the OSA indication, dosing is identical but the outcome being tracked is different, which is one more reason "how many mg" is the least interesting question — "toward what, monitored how" is the chart that matters.

The tirzepatide ladder, straight from the label

Mounjaro and Zepbound share one titration spine: 2.5 mg once weekly for weeks 1–4 — a starting dose, not intended as maintenance — then 5 mg. From there the label allows increases of 2.5 mg at intervals of at least 4 weeks, as tolerated: 7.5, 10, 12.5, up to a maximum of 15 mg weekly.

Maintenance is individualized: 5, 10, and 15 mg are the recommended maintenance doses, and plenty of people hold at 5 or 10 with good results rather than racing to the top. The trials’ headline numbers came from the maximum tolerated dose, but the label does not require anyone to reach it.

A missed dose is taken as soon as possible within about 4 days (96 hours); past that, skip it and resume the schedule — never take two doses within a shorter window than the label allows [verify exact wording on your label]. Escalations can be paused or stepped back if GI effects flare; that is management, not failure.

None of this transfers to compounded tirzepatide, where concentration varies by pharmacy and the vial in your refrigerator may not match the one in a chart. Your pharmacy label and prescriber govern; a website — this one included — does not.

What a schedule costs — the part dose charts leave out

Every rung on these ladders is also a line on an invoice, and the pricing model decides how. Under dose-laddered pricing, the chart is a revenue plan: a program quoting $149 at the starting dose and $299 at maintenance bills roughly $3,138 across a titration year (three entry months, nine at the top), while a flat-at-every-dose program at $169 bills $2,028 for the identical clinical path — an $1,100 gap produced entirely by pricing structure, not medicine. Four-week billing quietly adds another ~8.7%, because 28-day cycles land 13.04 times a year. Run your own quote through the tirzepatide or semaglutide dose-and-cost tool before signing anything.

Restarts have economics too. A gap — shortage, travel, finances — often means re-titrating from a lower rung for tolerability, and on laddered pricing that can mean paying “intro” months again while some programs also re-charge intake fees. Ask any program two questions before enrolling: what does my price become at each dose on this chart, and what happens to my rate if I pause and restart? A seller that answers in writing in one email is telling you something; a seller that answers with a phone-only “it depends” is telling you something too.

Finally, the label-to-insurance mapping: coverage follows the product and indication, not the molecule — which is why the same milligram can be covered as one brand and denied as another, and why compounded versions sit outside coverage entirely (cash-pay, sometimes HSA/FSA-eligible, which is not the same thing). The chart you titrate on and the label your plan reads are the same document; keep both in view.

A 2026-specific footnote: post-shortage, supply is a program-level variable again. Ask how a program handles a pharmacy backlog mid-titration — does your rate and rung hold, do they transfer the prescription, do they re-charge intake? A schedule is only as stable as the supply chain and pricing model underneath it, and both are fair questions before month one.

Safety, before anything else. Semaglutide and tirzepatide carry a boxed warning: thyroid C-cell tumors occurred in rodents, and the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop and seek care for severe, persistent abdominal pain (with or without vomiting) — the classic pancreatitis presentation. Gallbladder disease, dehydration-driven kidney injury, and hypoglycemia when combined with insulin or sulfonylureas are on the labels. Tell every clinician you take a GLP-1 before any procedure requiring sedation — anesthesia societies advise holding these drugs beforehand because of delayed stomach emptying [verify current guidance]. Do not use in pregnancy. In an emergency, call 911. Report side effects to your clinician and FDA MedWatch (1-800-FDA-1088).

Where this fits the pricing picture. Everything above describes the FDA-approved brand products and their labels. The compounded semaglutide and tirzepatide sold by the telehealth programs in our price index are not FDA-approved, are not reviewed for safety or effectiveness, and vary by pharmacy — trial results and label percentages do not transfer to them. If cost is what brought you here, start with the true-month calculator and the dose-and-cost ladders, and read the full safety page before comparing a single price. One more habit that pays: before enrolling anywhere, check whether the program publicly names its dispensing pharmacy — our pharmacy disclosure index tracks who does, because in a market of not-FDA-approved preparations, the pharmacy is the product and silence about it is information.

The bottom line

The Zepbound Dosage Chart is a topic where the label, the trials, and the marketing routinely tell three different stories. The version above sticks to the first two, flags what still needs verification, and leaves the clinical decisions where they belong — with a prescriber who knows your history. When you’re ready to compare what any of this costs in practice, the price index carries every price we track with its source and its date.

Questions worth bringing to your prescriber

Print or paraphrase; the point is walking in with structure. Which product and label are we dosing from, and why that one for me? What is our escalation plan — and our hold-the-rung plan if a step is rough? Which maintenance dose are we aiming for, and what result would make a lower one acceptable? What exactly should I do about a missed dose on this product — what window, and where is it written? If I pause for travel, illness, or cost, how do we restart — same rung or re-titrate? Do any of my other medications need timing changes around slowed stomach emptying? A prescriber who enjoys these questions is the one you want; a program whose intake flow can’t handle them is answering a different question — about itself.

How to read this article — and everything else on this site

House rules, so you can audit us: label claims cite labels, trial numbers cite the named trial, and a bracketed [verify] marks a figure our desk re-checks against the current source before each publication cycle rather than trusting memory. Dates matter as much as numbers — labels get revised, prices move — so treat anything undated (here or anywhere) as a rumor with good typography. Nothing above transfers to compounded copies: they are pharmacy preparations that are not FDA-approved, and a trial that tested the brand tested the brand. If you catch an error, [email protected] reaches a human with a 72-hour target; the corrections log shows we mean it.

Two more reading habits pay for themselves. First, separate frequency from severity: a 40% side effect that fades in a week and a 1% one that ends up in an emergency department are different kinds of facts, and sentences that blur them are selling something. Second, notice denominators — “in trials” means the approved product at protocol doses in monitored adults, which is the strongest evidence available and still not a promise about a different product, a different dose, or you.

Frequently asked questions

What are the units for a Zepbound vial?

The single-dose vial is exactly that — one labeled dose, drawn with the supplied syringe per the Instructions for Use. No conversion is required or appropriate; the whole vial is the dose.

Why won’t this site convert mg to units for compounded tirzepatide?

Because compounded concentrations vary by pharmacy and self-converted doses are a documented FDA error source. The pharmacy label governs; a generic table would be a hazard dressed as help.

Is Zepbound dosed differently for sleep apnea?

No — the OSA indication uses the same titration and maintenance doses. What differs is the outcome your clinician tracks.

Sources. FDA prescribing information for Wegovy, Ozempic, Rybelsus, Mounjaro, and Zepbound (dosage & administration sections); FDA drug-shortage and compounding communications. Figures marked [verify] are checked by a human editor against the current label before launch, per our editorial policy. Compounded products are not FDA-approved; label schedules describe the brand products only.